TRPV Antagonist

TRPV Antagonists (20):

Cat. No.	Product Name	Effect	Purity

HY-12245

SB-366791	Antagonist	98.11%
SB-366791 is a potent and selective vanilloid receptor (VR1/TRPV1) antagonist (IC₅₀=5.7 nM). SB-366791 can be used for the research of inflammation.

HY-132222

SET2	Antagonist	99.72%
SET2 is a selective TRPV2 antagonist (IC₅₀=0.46 μM). SET2 blocks the TRP channel and suppresses prostate cancer cells migration. SET2 reduces the lysophosphatidic acid (LPA, a TRPV2 activator)-induced cytoplasmic calcium increases.

HY-P1651B

SOR-C13 acetate	Antagonist	98.56%
SOR-C13 acetate is the acetate salt form of SOR-C13 (HY-P1651). SOR-C13 acetate is an antagonist for transient receptor potential vanilloid 6 (TRPV 6), with an IC₅₀ of 14 nM. SOR-C13 acetate inhibits tumor growth in SKOV-3 xenograft mouse model.

HY-P1651A

SOR-C13 TFA	Antagonist	99.18%
SOR-C13 TFA, a carboxy-terminal truncated peptide, is a high-affinity TRPV6 antagonist with an IC₅₀ value of 14 nM. TRPV6 is a non-voltage gated calcium channel that is associated with malignancy and poor prognosis in breast cancer. SOR-C13 TFA has anticancer activity.

HY-18662

RQ-00203078	Antagonist	99.84%
RQ-00203078 is a highly selective, potent and orally active TRPM8 antagonist with IC₅₀s of 5.3 nM and 8.3 nM for rat and human TRPM8 channels, respectively. RQ-00203078 shows little inhibitory action against TRPV1, TRPA1, TRPV4, or TRPM2 channels.

HY-100129

JNJ-17203212	Antagonist	99.94%
JNJ-17203212 is a selective, potent and competitive TRPV1 antagonist. JNJ-17203212 is developed for researching pain management, such as migraine.

HY-131868

TRPV3 antagonist 74a	Antagonist	99.85%
TRPV3 antagonist 74a is a potent and selective TRPV3 antagonist. TRPV3 antagonist 74a displays no significant activity against a panel of other ion channels. TRPV3 antagonist 74a can be used for the research of neuropathic pain.

HY-144372

TRPV1 antagonist 3	Antagonist	99.30%
TRPV1 antagonist 3 (Compound 7q) is a potent TRPV1 antagonist with an IC₅₀ of 2.66 nM against capsaicin. TRPV1 antagonist 3 is mode-selective, oral bioavailable (F = 60%) and CNS-penetrant.

HY-114017

Vanilloid receptor antagonist 1	Antagonist	99.54%
Vanilloid receptor antagonist 1 is a potent vanilloid receptor TRPV1 antagonist extracted from patent US8349852B2, compound B8.

HY-P1651

SOR-C13	Antagonist	98.56%
SOR-C13, a carboxy-terminal truncated peptide, is a high-affinity TRPV6 antagonist with an IC₅₀ value of 14 nM. TRPV6 is a non-voltage gated calcium channel that is associated with malignancy and poor prognosis in breast cancer. SOR-C13 has anticancer activity.

HY-10635

ABT-102	Antagonist
ABT-102 is a potent and highly selective Vanilloid Receptor (TRPV1) receptor antagonist. ABT-102 potently and reversibly increases heat pain thresholds and reduced painfulness of suprathreshold oral/cutaneous heat. ABT-102 reduces nociceptive responses of animals in models of inflammatory, bone cancer, postoperative, and osteoarthritic pain.

HY-160900

RN-1665	Antagonist	99.93%
RN-1665 is an orally active TRPV4 antagonist that exhibits excellent selectivity for related TRP receptors such as TRPV1, TRPV3 and TRPM8. RN-1665 is a TRPV4 probe for focus screens, with IC50s of 0.26 μM and 0.39 μM for hTRPV4 and rTRPV4 from human and rat, respectively.

HY-149823

TRPV4 antagonist 4	Antagonist
TRPV4 antagonist 4 is a potent TRPV4 antagonist with an IC₅₀ value of 22.65 nM. TRPV4 antagonist 4 inhibits TRPV4 current. TRPV4 antagonist 4 shows protective effects on acute lung injury.

HY-19589

JTS-653	Antagonist
JTS-653 is a highly potent and selective transient receptor potential vanilloid 1 (TRPV1) antagonist in vitro and in vivo. JTS-653 attenuates chronic pain refractory to non-steroidal anti-inflammatory agents.

HY-P1175A

L-R4W2 TFA	Antagonist
L-R4W2 TFA is a potent antagonist of vanilloid receptor 1 (VR1, TRPV1), with an IC₅₀ of 0.1 μM. L-R4W2 TFA may act as a potent analgesic.

HY-108453

5-Iodoresiniferatoxin	Antagonist
5-Iodoresiniferatoxin (I-RTX) is a selective TRPV1 antagonist, with an IC₅₀s of 0.7 and 5.4 nM for rat and human receptors, respectively. 5-Iodoresiniferatoxin induces TRPV1-dependent hypothermia in vivo.

HY-P1175

L-R4W2	Antagonist
L-R4W2 is a potent antagonist of vanilloid receptor 1 (VR1, TRPV1), with an IC₅₀ of 0.1 μM. L-R4W2 may act as a potent analgesic.

HY-W517163

MK-2295	Antagonist
MK-2295 (NGD-8243) is a TRPV1 antagonist. MK-2295 is an analgesic agent, and can be used for research of pain.

HY-111218

TRPV1 antagonist 5	Antagonist
TRPV1 antagonist 5 (compound 1) is a potent TRPV1 antagonist.

HY-12914

V116517	Antagonist
V116517 is a potent, orally active transient receptor potential vanilloid (TRPV1) antagonist. V116517 shows potent activity in inhibiting both capsaicin (CAP)- and acid (pH 5)-induced currents in rat DRG neurons expressing native TRPV (IC₅₀=423.2 nM for CAP; IC₅₀=180.3 nM for acid). V116517 can be used for the research of pain.

Name
Email *

	Sorry, but the email address you supplied was invalid.